gms | German Medical Science

MAINZ//2011: 56. GMDS-Jahrestagung und 6. DGEpi-Jahrestagung

Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V.
Deutsche Gesellschaft für Epidemiologie e. V.

26. - 29.09.2011 in Mainz

Factors predicting survival after diagnosis of laryngeal cancer

Meeting Abstract

  • Heribert Ramroth - Institut für Public Health, Heidelberg
  • Anja Schoeps - Institut für Public Health, Heidelberg
  • Elisabeth Rudolph - Institut für Public Health, Heidelberg
  • Gerhard Dyckhoff - HNO-Universitätsklinik, Heidelberg
  • Andreas Dietz - HNO-Universitätsklinik, Leipzig
  • Heiko Becher - Institut für Public Health, Heidelberg

Mainz//2011. 56. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (gmds), 6. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi). Mainz, 26.-29.09.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11gmds330

doi: 10.3205/11gmds330, urn:nbn:de:0183-11gmds3301

Veröffentlicht: 20. September 2011

© 2011 Ramroth et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Background: During the recent years, the incidence of laryngeal cancer was relatively stable, where the age-standardised incidence rates vary strongly between the sexes, with 5.1 (men) and 0.6 (women) new cases per 100,000 per year [1]. While the age-standardised incidence and mortality rates in men slowly decreased during the recent years, the rates in women rather increased. Five-year overall survival of all Europeans diagnosed with laryngeal cancer between 1995 and 1999 was 55%, slightly worse than survival rates for the German population (59%) [2]. However, survival has not increased remarkably within the last years [3] – and a variety of interacting factors are presumed to predict survival after diagnosis: tumour stage, tumour site, treatment approaches, age and comorbidities [4], [5].

Objective: The aim of this study is to present results from a multivariate analysis based on the currently largest German patient cohort diagnosed with laryngeal cancer.

Methods: A retrospective cohort study was conducted in four hospitals in South-West Germany. Incident cases with laryngeal squamous cell carcinoma were included for the years 1998-2004. Multivariate regression analysis was performed using the Cox proportional hazards model.

Results: 594 patients were observed with a mean follow-up of 64.1 months. Overall 5-year survival was 66% (95% confidence-interval (CI): 62-70%). The strongest risk factors in multivariate analysis were age at first diagnosis (Hazard Ratio (HR): 1.5; 95%CI: 1.5-1.7 per each additional 10 years) and the development of recurrences (HR 3.1; 95%CI: 2.3-4.2) or second primary carcinomas (HR 2.1; 95%CI: 1.4-3.1). Tumour site and tumour stage were further significant predictors for survival. A somewhat weaker effect was shown for patients with comorbidities (using Charlson’s comorbidity index). The choice of treatment did not affect survival when adjusting for other factors, possibly because the optimal treatment approach was applied for the specific constitution and requirements of each patient.

Discussion: For future research it would be desirable to study the effect of treatment on quality of life in multivariate analysis as well as other modifiable risk factors as smoking and drinking reduction or cessation after diagnosis.


Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009;45(6):931-91.
Piccirillo JF, Lacy PD, Basu A, Spitznagel EL. Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg. 2002;128(10):1172-9.
Nguyen-Tan PF, Le QT, Quivey JM, Singer M, Terris DJ, Goffinet DR, Fu KK. Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys. 2001;50(5):1172-80.
Rudolph E, Dyckhoff G, Becher H, Dietz A, Ramroth H. Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. Eur Arch Otorhinolaryngol. 2011;268(2):165-79.